PDC takes into account the characteristics of both large and small molecules. Therefore, in vitro ADME research on it needs to take into account homing peptides, linkers, payloads, and PDC. In the early stages of drug development, if the homing peptide is in the form of a polypeptide drug, it is prone to hydrolysis and has poor stability. Its stability and targeting in plasma should be considered; at the same time, the two forms of the linker will produce different metabolic results, and the released payload (including the payload connected to the same part of the linker) is a small molecule cytotoxic drug. It is crucial to determine the metabolites of these drugs for drug development. Therefore, PDC composed of homing peptides, linkers, and payloads needs to be studied in plasma stability, plasma protein binding, metabolite identification, etc., which is of great significance for the early development of PDC drugs!
IPHASE "One-stop" product solution for in vitro DMPK research
As a leader in in vitro research biological reagents, IPHASE follows the forefront of drug development and develops a variety of in vitro biological reagents at multiple levels and fields targeting the in vitro DMPK research direction of PDC drugs to help PDC drug development research!
1.Subcellular fraction reagents
·Liver microsomes ·Liver S9/Acidified Liver S9
·Liver cytosol ·Kidney S9
·Lysosome ·Acidified liver homogenate
2.Primary Hepatocyte Products
·Human/Monkey/Dog/Rat/Mouse/Minipig Suspended/Adherent Primary Hepatocytes
3.Transporter Products
·ABC family transporters ·SLC family transporters
4.Recombinant enzyme products
·CYP ·UGT
5.Plasma related products
·Equilibrium dialysis devices ·Plasma stability test products
·Plasma protein binding reagents
6.Blank biological matrix
Post time: 2024-08-16 15:26:10